325 related articles for article (PubMed ID: 36077354)
1. LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors.
Sauer N; Szlasa W; Jonderko L; Oślizło M; Kunachowicz D; Kulbacka J; Karłowicz-Bodalska K
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077354
[TBL] [Abstract][Full Text] [Related]
2. The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application.
Huo JL; Wang YT; Fu WJ; Lu N; Liu ZS
Front Immunol; 2022; 13():956090. PubMed ID: 35958563
[TBL] [Abstract][Full Text] [Related]
3. Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy.
Qian Y; Sun Y; Shi P; Zhou X; Zhang Q; Dong Q; Jin S; Qiu L; Niu X; Zhou X; Zhao W; Wu Y; Zhai W; Gao Y
Acta Pharm Sin B; 2024 Mar; 14(3):1150-1165. PubMed ID: 38486998
[TBL] [Abstract][Full Text] [Related]
4. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target.
Qian W; Zhao M; Wang R; Li H
J Hematol Oncol; 2021 Sep; 14(1):147. PubMed ID: 34526102
[TBL] [Abstract][Full Text] [Related]
5. Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.
Wang J; Sanmamed MF; Datar I; Su TT; Ji L; Sun J; Chen L; Chen Y; Zhu G; Yin W; Zheng L; Zhou T; Badri T; Yao S; Zhu S; Boto A; Sznol M; Melero I; Vignali DAA; Schalper K; Chen L
Cell; 2019 Jan; 176(1-2):334-347.e12. PubMed ID: 30580966
[TBL] [Abstract][Full Text] [Related]
6. PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy.
Shi N; Zhou Y; Liu Y; Zhang R; Jiang X; Ren C; Gao X; Luo L
Front Immunol; 2022; 13():1047610. PubMed ID: 36518768
[TBL] [Abstract][Full Text] [Related]
7. Emerging immune checkpoints for cancer therapy.
Li X; Hu W; Zheng X; Zhang C; Du P; Zheng Z; Yang Y; Wu J; Ji M; Jiang J; Wu C
Acta Oncol; 2015 Nov; 54(10):1706-13. PubMed ID: 26361073
[TBL] [Abstract][Full Text] [Related]
8. Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients.
Wang H; Mao L; Zhang T; Zhang L; Wu Y; Guo W; Hu J; Ju H; Ren G
J Oral Pathol Med; 2019 Sep; 48(8):669-676. PubMed ID: 31132187
[TBL] [Abstract][Full Text] [Related]
9. Lymphocyte-activation gene-3, an important immune checkpoint in cancer.
He Y; Rivard CJ; Rozeboom L; Yu H; Ellison K; Kowalewski A; Zhou C; Hirsch FR
Cancer Sci; 2016 Sep; 107(9):1193-7. PubMed ID: 27297395
[TBL] [Abstract][Full Text] [Related]
10. Development of a high-throughput TR-FRET screening assay for LAG-3/FGL1 interaction.
Abdel-Rahman SA; Zhang L; Gabr MT
SLAS Discov; 2023 Jun; 28(4):188-192. PubMed ID: 37121273
[TBL] [Abstract][Full Text] [Related]
11. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.
Kreidieh FY; Tawbi HA
Ther Adv Med Oncol; 2023; 15():17588359231186027. PubMed ID: 37484526
[TBL] [Abstract][Full Text] [Related]
12. The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer.
Kozłowski M; Borzyszkowska D; Cymbaluk-Płoska A
Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359346
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
14. Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma.
Harris-Bookman S; Mathios D; Martin AM; Xia Y; Kim E; Xu H; Belcaid Z; Polanczyk M; Barberi T; Theodros D; Kim J; Taube JM; Burger PC; Selby M; Taitt C; Korman A; Ye X; Drake CG; Brem H; Pardoll DM; Lim M
Int J Cancer; 2018 Dec; 143(12):3201-3208. PubMed ID: 30248181
[TBL] [Abstract][Full Text] [Related]
15. On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment.
Tundo GR; Sbardella D; Lacal PM; Graziani G; Marini S
Chemotherapy; 2019; 64(2):62-80. PubMed ID: 31387102
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with Nivolumab.
Thudium K; Selby M; Zorn JA; Rak G; Wang XT; Bunch RT; Hogan JM; Strop P; Korman AJ
Cancer Immunol Res; 2022 Oct; 10(10):1175-1189. PubMed ID: 35981087
[TBL] [Abstract][Full Text] [Related]
17. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
18. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
[TBL] [Abstract][Full Text] [Related]
19. LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures.
Gestermann N; Saugy D; Martignier C; Tillé L; Fuertes Marraco SA; Zettl M; Tirapu I; Speiser DE; Verdeil G
Oncoimmunology; 2020; 9(1):1736792. PubMed ID: 32850194
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
